JP6444399B2 - 癌の処置に用いるための硫酸化多糖 - Google Patents

癌の処置に用いるための硫酸化多糖 Download PDF

Info

Publication number
JP6444399B2
JP6444399B2 JP2016525966A JP2016525966A JP6444399B2 JP 6444399 B2 JP6444399 B2 JP 6444399B2 JP 2016525966 A JP2016525966 A JP 2016525966A JP 2016525966 A JP2016525966 A JP 2016525966A JP 6444399 B2 JP6444399 B2 JP 6444399B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
platelets
cell
heparin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016525966A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534078A (ja
JP2016534078A5 (enExample
Inventor
ハンス−アケ ファブリシウス
ハンス−アケ ファブリシウス
Original Assignee
セル レセプター アーゲー
セル レセプター アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セル レセプター アーゲー, セル レセプター アーゲー filed Critical セル レセプター アーゲー
Publication of JP2016534078A publication Critical patent/JP2016534078A/ja
Publication of JP2016534078A5 publication Critical patent/JP2016534078A5/ja
Application granted granted Critical
Publication of JP6444399B2 publication Critical patent/JP6444399B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0057—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016525966A 2013-10-22 2014-10-22 癌の処置に用いるための硫酸化多糖 Active JP6444399B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102013111630.2 2013-10-22
DE102013111630 2013-10-22
PCT/EP2014/072620 WO2015059177A1 (en) 2013-10-22 2014-10-22 Sulfated polysaccharides for use in the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2016534078A JP2016534078A (ja) 2016-11-04
JP2016534078A5 JP2016534078A5 (enExample) 2017-01-19
JP6444399B2 true JP6444399B2 (ja) 2018-12-26

Family

ID=51795625

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016525966A Active JP6444399B2 (ja) 2013-10-22 2014-10-22 癌の処置に用いるための硫酸化多糖

Country Status (6)

Country Link
US (1) US10098906B2 (enExample)
EP (1) EP3060223B1 (enExample)
JP (1) JP6444399B2 (enExample)
AU (1) AU2014339000B2 (enExample)
CA (1) CA2926888C (enExample)
WO (1) WO2015059177A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196256A2 (en) 2015-06-04 2016-12-08 University Of North Carolina At Greensboro Non-aromatic difluoro analogues of resorcylic acid lactones
US11191743B2 (en) * 2016-01-11 2021-12-07 Dignity Health Modulators of zinc activated cation channel
CA3072856A1 (en) 2017-08-23 2019-02-28 Cell Receptor AG Combination of a mapk/erk pathway inhibitor and a glycosaminoglycan for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
US7781416B2 (en) * 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US20060154894A1 (en) * 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
WO2010096466A2 (en) * 2009-02-17 2010-08-26 Novelmed Therapeutics, Inc. Methods and compositions for inhibiting cellular proliferation and surgical adhesion
CN102917711A (zh) * 2010-03-12 2013-02-06 澳大利亚国立大学 硫酸乙酰肝素替代疗法
IT1401253B1 (it) * 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
TWI520740B (zh) * 2011-02-02 2016-02-11 模範健康科技私人企業有限公司 利用多硫酸化多醣之骨髓水腫（水腫）的治療
DK2861273T3 (da) * 2012-06-13 2017-11-27 Exthera Medical Corp Anvendelse af heparin og kulhydrater til behandling af cancer.
EP3131534A4 (en) * 2014-04-17 2017-12-20 Memorial Sloan Kettering Cancer Center Fucoidan nanogels and methods of their use and manufacture

Also Published As

Publication number Publication date
EP3060223B1 (en) 2017-08-30
EP3060223A1 (en) 2016-08-31
JP2016534078A (ja) 2016-11-04
AU2014339000A1 (en) 2016-04-28
US20160367589A1 (en) 2016-12-22
WO2015059177A1 (en) 2015-04-30
CA2926888C (en) 2020-03-24
AU2014339000B2 (en) 2017-05-18
CA2926888A1 (en) 2015-04-30
US10098906B2 (en) 2018-10-16

Similar Documents

Publication Publication Date Title
Tan et al. Chondroitin-6-sulfate attenuates inflammatory responses in murine macrophages via suppression of NF-κB nuclear translocation
RS57214B1 (sr) Upotreba derivata hemijski modifikovanog heparina za bolest srpastih ćelija
da Cunha et al. Do chondroitin sulfates with different structures have different activities on chondrocytes and macrophages?
Zhang et al. Mechanistic insights into cellular immunity of chondroitin sulfate A and its zwitterionic N-deacetylated derivatives
WO2018165656A1 (en) Short-acting heparin-based anticoagulant compounds and methods
JP6205350B2 (ja) 同じ多糖鎖の４位または６位でバイオテクノロジー的に硫酸化されたコンドロイチン硫酸、およびその調整方法
JP6444399B2 (ja) 癌の処置に用いるための硫酸化多糖
Wang et al. Heparanase affects secretory granule homeostasis of murine mast cells through degrading heparin
Volpi Condrosulf®: structural characterization, pharmacological activities and mechanism of action
JP6753610B2 (ja) Ｎ−脱硫酸化グリコサミノグリカンの誘導体、及び薬物としての使用
CA2598331A1 (en) Amide derivatives of hyaluronic acid in osteoarthrosis
US11559544B2 (en) Combination of a MAPK/ERK pathway inhibitor and a glycosaminoglycan for the treatment of cancer
JPH05503506A (ja) 芳香族ポリマーを含む薬学的組成物及びそれを用いる治療法
Oreste et al. Semi-synthetic heparinoids
US7618652B2 (en) Glycosaminoglycan anticoagulants derived from fish
Balazs et al. Interaction of amino sugars and amino sugar-containing macromolecules with viruses, cells, and tissues
WO2002083155A1 (en) Use of sulfated bacterial polysaccharides suitable for the inhibition of angiogenesis
Arumugam et al. Biological activities of heparan sulfate
JP2005290383A (ja) ６−ｏ−硫酸化ｎ−アセチルヘパロサン及び造血幹細胞増殖助剤
JP4463510B2 (ja) グリア瘢痕形成抑制剤
Khurshid Characterisation of a novel bioactive complex polysaccharide from a marine invertebrate with potent anticancer and antimalarial activities
JP2017519731A (ja) ウルバンを含む関節炎を治療するための関節内補充組成物
US20170312305A1 (en) Pharmaceutical extracts and uses thereof
Biswas et al. Heparin: A Conventional Drug with a New Prototype

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181127

R150 Certificate of patent or registration of utility model

Ref document number: 6444399

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250